Working… Menu

Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries. (AMYLCAR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03232632
Recruitment Status : Terminated (intervention programming)
First Posted : July 28, 2017
Last Update Posted : August 26, 2020
Information provided by (Responsible Party):
University Hospital, Toulouse

Brief Summary:
To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.

Condition or disease Intervention/treatment Phase
Cardiac Amyloidosis Drug: PET with 18 F-Flutemetamol Early Phase 1

Detailed Description:

Hypothesis had been performed that PET with 18F-Flutemetamol (Vizamyl®) could lead an early diagnostic. Indeed, this tracer had been recently used to highlight inter-cerebral beta-amyloid plaques on patients with Alzheimer Disease.

Because this labelling is performed on amyloid deposits, this tracer would lead to view and to quantify amyloid deposits within cardiac amyloid injuries.

Results of this PET will be combined with scan examinations for a better anatomic tracking.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Supportive Care
Official Title: Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries.
Actual Study Start Date : March 15, 2017
Actual Primary Completion Date : September 15, 2019
Actual Study Completion Date : September 15, 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Amyloidosis

Arm Intervention/treatment
Experimental: PET with 18 F-Flutemetamol
PET with 18 F-Flutemetamol (Vizamyl®) = product under Alzheimer's disease indication
Drug: PET with 18 F-Flutemetamol
PET with 18 F-Flutemetamol (Vizamyl ®)
Other Name: Vizamyl®

Primary Outcome Measures :
  1. ratio Heart/ Upper Mediastinum [ Time Frame: average of last 15 minutes ]
    peak of 18F-Flutemetamol capture

  2. standardized uptake value (SUV) measures [ Time Frame: average of last 15 minutes ]
    standardized uptake value (SUV) measures

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients followed for amyloidosis with proved cardiac injury or strongly suspected:

    • cardiac echography with typical signs of amyloid injury,
    • anatomical result confirming presence of amyloid deposits at cardiac or peripheral level
  • Signature of Informed Consent Form,
  • Affiliation to a social security system

Exclusion Criteria:

  • Patient who suffers from another pathology which could lead cardiac injury (coronary disease, valvular disease, other pathology of deposit),
  • Pregnancy and lactating women,
  • Absence of effective contraception,
  • Irradiating examination performed within the last 12 months or scheduled within the next 12 months,
  • Unable patient physically, mentally or legally to provide informed consent,
  • Patient under a system of legal protection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03232632

Layout table for location information
University Hospital Toulouse
Toulouse, France, 31000
Sponsors and Collaborators
University Hospital, Toulouse
Layout table for investigator information
Principal Investigator: Eric OUHAYOUN, MD University Hospital, Toulouse
Layout table for additonal information
Responsible Party: University Hospital, Toulouse Identifier: NCT03232632    
Other Study ID Numbers: 13 199 02
First Posted: July 28, 2017    Key Record Dates
Last Update Posted: August 26, 2020
Last Verified: August 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Proteostasis Deficiencies
Metabolic Diseases
Molecular Mechanisms of Pharmacological Action